Grufity logoGrufity logo

Nuvation Bio Inc Stock Research

NUVB

1.64USD-0.02(-1.20%)Market Closed

Market Summary

USD1.64-0.02
Market Closed
-1.20%

NUVB Stock Price

NUVB RSI Chart

NUVB Valuation

Market Cap

358.6M

Price/Earnings (Trailing)

-3.44

Price/Sales (Trailing)

48.14

EV/EBITDA

-2.48

Price/Free Cashflow

-3.73

NUVB Price/Sales (Trailing)

NUVB Profitability

EBT Margin

-2247.06%

Return on Equity

-16.24%

Return on Assets

-15.8%

Free Cashflow Yield

-26.8%

NUVB Fundamentals

NUVB Revenue

Revenue (TTM)

7.4M

Revenue Y/Y

290.58%

Revenue Q/Q

65.63%

NUVB Earnings

Earnings (TTM)

-104.2M

Earnings Y/Y

17.06%

Earnings Q/Q

23.37%

Price Action

52 Week Range

1.559.81
(Low)(High)

Last 7 days

-2.4%

Last 30 days

-20.4%

Last 90 days

-7.3%

Trailing 12 Months

-69.5%

NUVB Financial Health

Current Ratio

48.63

NUVB Investor Care

Shares Dilution (1Y)

0.31%

Diluted EPS (TTM)

-0.48

Financials for Nuvation Bio

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue54.3%7,448,0004,828,0003,548,0003,483,0002,963,000
Operating Expenses-4.2%119,734,000125,009,000118,462,000101,026,00093,318,000
  S&GA Expenses-0.4%31,919,00032,062,00029,687,00027,139,00024,281,000
  R&D Expenses-5.5%87,815,00092,947,00088,775,00073,887,00069,037,000
EBITDA-5.1%-108,279,000-103,041,000-87,539,000-86,664,000-
EBITDA Margin22.8%-22.43-29.04-25.13-29.25-
Earnings Before Taxes4.0%-104,199,000-108,488,000-103,264,000-87,739,000-86,848,000
EBT Margin22.8%-22.47-29.10-25.19-29.31-
Net Income4.0%-104,199,000-108,488,000-103,264,000-87,739,000-86,848,000
Net Income Margin22.8%-22.47-29.10-25.19-29.31-
Free Cahsflow-17.0%-103,382,000-88,390,000-107,790,000-68,190,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-2.1%672686720752776
  Current Assets-2.1%667681714748772
    Cash Equivalents-27.1%101139102106132
  Net PPE-0.9%1.001.001.001.001.00
Liabilities-8.0%17.0019.0027.0028.0030.00
  Current Liabilities-6.1%13.0014.0021.0021.0017.00
Shareholder's Equity-1.9%655668693724746
  Retained Earnings-8.5%-267-246-218-184-162
Shares Outstanding0.1%219218218218218
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations7.0%-96.10-103-88.43-78.36-68.19
  Share Based Compensation15.5%16.0014.0014.0011.009.00
Cashflow From Investing161.0%63.00-103-259-459-454
Cashflow From Financing-9.0%1.001.001.005.00626

Risks for NUVB

What is the probability of a big loss on NUVB?

81.6%


Probability that Nuvation Bio stock will be more than 20% underwater in next one year

76.5%


Probability that Nuvation Bio stock will be more than 30% underwater in next one year.

65.4%


Probability that Nuvation Bio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NUVB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Nuvation Bio was unfortunately bought at previous high price.

Drawdowns

Returns for NUVB

Cumulative Returns on NUVB

Which funds bought or sold NUVB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-0.05
-5,177
29,823
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
unchanged
-
-745
9,255
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-14,356
88,644
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-3,000
-
-%
2023-02-16
AXXCESS WEALTH MANAGEMENT, LLC
sold off
-100
-22,000
-
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
added
7.61
-28,244
336,756
-%
2023-02-15
Metropolitan Life Insurance Co/NY
unchanged
-
-2,552
14,448
-%
2023-02-15
Virtu Financial LLC
new
-
31,000
31,000
-%
2023-02-15
Point72 Middle East FZE
new
-
6,015
6,015
-%
2023-02-15
JANE STREET GROUP, LLC
added
0.53
-48,604
303,396
-%

1–10 of 49

Latest Funds Activity

Are funds buying NUVB calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NUVB
No. of Funds

Nuvation Bio News

Best Stocks

Exploring the Potential of Nuvation Bio: Bullish Ratings, Mixed ....

Best Stocks,
6 hours ago

Defense World

OppFi (NYSE:OPFI) PT Lowered to $2.50.

Defense World,
25 hours ago

Insider Monkey

Schedule 13G FIlings of Nuvation Bio

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
deep track capital, lp
3.76%
8,221,188
SC 13G/A
Feb 13, 2023
blackrock inc.
5.0%
10,996,735
SC 13G
Feb 13, 2023
omega fund v, l.p.
6.9%
15,072,340
SC 13D/A
Feb 09, 2023
vanguard group inc
4.55%
9,932,441
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Jun 23, 2022
deep track capital, lp
5.26%
11,471,281
SC 13G
Feb 11, 2022
castle creek arbitrage, llc
10%
215,426
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 19, 2021
omega fund v, l.p.
13.0%
28,212,376
SC 13D
Feb 19, 2021
hung david
27.4%
59,645,012
SC 13D

NUVB Fair Value

Nuvation Bio fair value in different scenarios

The table shows the Fair Value estimates for Nuvation Bio for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.78

-52.44%

0.79

-51.83%

0.81

-50.61%

0.85

-48.17%

0.93

-43.29%
Current Inflation

0.78

-52.44%

0.79

-51.83%

0.81

-50.61%

0.84

-48.78%

0.91

-44.51%
Very High Inflation

0.78

-52.44%

0.79

-51.83%

0.80

-51.22%

0.83

-49.39%

0.88

-46.34%

Historical Nuvation Bio Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Nuvation Bio

View All Filings
Date Filed Form Type Document
Mar 16, 2023
S-8
Employee Benefits Plan
Mar 15, 2023
10-K
Annual Report
Mar 15, 2023
8-K
Current Report
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading
Mar 02, 2023
4
Insider Trading

Latest Insider Trading transactions for NUVB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-12-05
FALBERG KATHRYN E
bought
83,961
1.9526
43,000
-
2022-12-02
FALBERG KATHRYN E
bought
93,186
1.9827
47,000
-
2022-12-01
FALBERG KATHRYN E
bought
167,599
1.9727
84,959
-
2022-11-30
FALBERG KATHRYN E
bought
139,088
1.8535
75,041
-
2022-04-05
Omega Fund V, L.P.
sold
-14,000,000
5.6
-2,500,000
-
2021-12-15
Omega Fund V, L.P.
sold
-5,035,000
10.07
-500,000
-
2021-12-07
Omega Fund V, L.P.
sold
-13,720,000
9.8
-1,400,000
-
2021-11-24
NODELMAN OLEG
bought
1,254,860
7.6859
163,268
-
2021-11-24
NODELMAN OLEG
bought
167,230
7.6859
21,758
-
2021-11-23
Omega Fund V, L.P.
sold
-351
9.75
-36.00
-

1–10 of 38

David T. Hung
60
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

NUVB Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:  
Research and development$ 87,815$ 69,037
General and administrative31,91924,281
Total operating expenses119,73493,318
Loss from operations(119,734)(93,318)
Other income (expense):  
Interest income7,4482,963
Investment advisory fees(872)(644)
Change in fair value of warrants liability10,1874,231
Net (loss) gain on marketable securities(1,228)(80)
Total other income (expense), net15,5356,470
Loss before income taxes(104,199)(86,848)
Provision for income taxes00
Net loss$ (104,199)$ (86,848)
Net loss per share attributable to common stockholders, basic$ (0.48)$ (0.44)
Net loss per share attributable to common stockholders, diluted$ (0.48)$ (0.44)
Weighted average common shares outstanding, basic216,721197,887
Weighted average common shares outstanding, diluted216,721197,887
Comprehensive loss:  
Net loss$ (104,199)$ (86,848)
Other comprehensive income (loss), net of taxes:  
Unrealized loss on available-for-sale securities, net(4,341)(2,742)
Comprehensive loss$ (108,540)$ (89,590)

NUVB Balance Sheet

2022-12-31
Consolidated Balance Sheet - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets  
Cash equivalents$ 101,099$ 132,423
Prepaid expenses and other current assets3,8193,642
Marketable securities559,915632,969
Interest receivable on marketable securities2,4853,039
Total Current Assets667,318772,073
Property and equipment, net894786
Lease security deposit138421
Right of use asset3,7912,871
Total Assets672,141776,151
Current liabilities  
Accounts payable2,1393,925
Current operating lease liabilities1,206863
Accrued expenses9,81612,137
Total Current Liabilities13,16116,925
Warrant Liability85011,037
Non-current operating lease liabilities3,0542,192
Total Liabilities17,06530,154
Commitments and contingencies
Stockholders' Equity  
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000 (Class A 1,000,000,000,Class B 60,000,000) and 1,174,094,678 (Class A 880,000,000, Class B 294,094,678) shares authorized as of December 31, 2021 and December 31, 2020, respectively, 217,948,568 (Class A 216,948,568, Class B 1,000,000) and 149,042,155 (Class A 91,397,142, Class B 57,645,013) shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively927,604909,985
Accumulated deficit(267,002)(162,803)
Accumulated other comprehensive (loss) income(5,526)(1,185)
Total Stockholders' Equity655,076745,997
Total Liabilities and Stockholders' Equity$ 672,141$ 776,151